Novo Sees Ozempic Substitute Ready When Patent Ends: Berlingske

Novo Nordisk will have new replacement drugs ready when the patents on Ozempic and Wegovy expire in Europe in 2031 and in the US in 2032, newspaper Berlingske quotes Chief Scientific Officer Martin Holst Lange as saying.

• Novo expects that some of the drug candidates going through clinical trials this year should be ready to be submitted for approval in 2030, Lange says, according to Berlingske
• Novo will provide more detail on its pipeline at a capital markets day in London in September, the CSO tells the newspaper

To contact the reporter on this story:
Christian Wienberg in Copenhagen at ...